Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
The Study of Oligodendrocyte Progenitor Cells in Down Syndrome for Therapeutic Interventions
EF 2022-23
Résumé
Down syndrome (DS) is the most common chromosomal condition and almost always presents with learning, language, and memory deficits that results in lifelong disability. DS is a developmental disorder, but individuals with DS also experience premature aging—a common feature among many neurodegenerative diseases. Oligodendrocyte progenitor cells (OPCs) are thought to form myelin sheaths in the central nervous system, but emerging evidence suggests their ability to phagocytose synapses. Additionally, premature senescent OPCs enter an irreversible state of cell cycle arrest, lose functionality, and release factors that exacerbate inflammation. To date, the molecular mechanisms and age-related progression of inflammation-associated neurodegeneration in DS remain unclear. On this basis, the Ts65Dn mouse model—that has several regions of conserved synteny with humans, as well as exhibits craniofacial dysmorphology and behavioural abnormalities—will be used to uncover the diverse roles of OPCs in the pathogenesis of DS in humans. I will study the development of the DS brain in mice to determine the mechanism by which OPCs phagocytose synapses and contribute to altered synaptic morphology. The visualization of progressive synapse loss will be correlated with the cognitive decline identified from established behavioural tests. During various timepoints in brain development, DS mice will be subjected to administrations of Fisetin to test whether senescence-reducing therapies decrease cortical inflammation, increase myelination, as well as ameliorate learning and memory deficits. The goal of this study is to identify translational therapeutic tools to prevent neurodegeneration in DS—with implications to treat demyelinating and neurodevelopmental disorders as well.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
486316
Name
Feng Min Yi
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The Study of Oligodendrocyte Progenitor Cells in Down Syndrome for Therapeutic Interventions
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Demyelinating Disease; Down Syndrome; Impaired Neurogenesis; Nervous System; Neurodegeneration; Neuroinflammation; Premature Aging; Senescence; Synapse Morphology; Therapeutic Interventions
Abstract
Down syndrome (DS) is the most common chromosomal condition and almost always presents with learning, language, and memory deficits that results in lifelong disability. DS is a developmental disorder, but individuals with DS also experience premature aging—a common feature among many neurodegenerative diseases. Oligodendrocyte progenitor cells (OPCs) are thought to form myelin sheaths in the central nervous system, but emerging evidence suggests their ability to phagocytose synapses. Additionally, premature senescent OPCs enter an irreversible state of cell cycle arrest, lose functionality, and release factors that exacerbate inflammation. To date, the molecular mechanisms and age-related progression of inflammation-associated neurodegeneration in DS remain unclear. On this basis, the Ts65Dn mouse model—that has several regions of conserved synteny with humans, as well as exhibits craniofacial dysmorphology and behavioural abnormalities—will be used to uncover the diverse roles of OPCs in the pathogenesis of DS in humans. I will study the development of the DS brain in mice to determine the mechanism by which OPCs phagocytose synapses and contribute to altered synaptic morphology. The visualization of progressive synapse loss will be correlated with the cognitive decline identified from established behavioural tests. During various timepoints in brain development, DS mice will be subjected to administrations of Fisetin to test whether senescence-reducing therapies decrease cortical inflammation, increase myelination, as well as ameliorate learning and memory deficits. The goal of this study is to identify translational therapeutic tools to prevent neurodegeneration in DS—with implications to treat demyelinating and neurodevelopmental disorders as well.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Feng, Min Yi
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~